Are You Falling for These 5 Medicare Myths?

Medicare guidance clarifies plan distinctions, enrollment windows, costs and new utilization controls: 2026 deductibles are $1,736 for Part A and $283 for Part B (increases of $60 and $26 versus 2025), Part B monthly premium is $202.90 (up from $185), and IRMAA surcharges begin above $109,000 individual/$218,000 joint income. The piece highlights late-enrollment penalties (10% per 12 months for Part B; Part D penalty calculated from a $38.99 base), a six-state pilot requiring prior authorizations (NJ, OH, OK, TX, AZ, WA), and recommended use of Medigap during the six-month post-65 Part B enrollment window — developments that are likely to modestly influence retiree out-of-pocket spending, insurance product demand, and utilization patterns for insurers and healthcare providers.

Analysis

Market structure: The immediate winners are Medicare Advantage and Part D incumbents (UnitedHealth UNH, Humana HUM, CVS/Cigna CVS/CI) who can monetize enrollment flows and formularies as Original Medicare becomes more restrictive; Medigap writers also gain if supplemental demand rises. Losers are providers and device makers exposed to elective orthopedics and skin grafts (HCA, UHS, Stryker SYK, Zimmer ZBH) in the six pilot states where prior authorization will reduce utilization and extend payment cycles. Insurers gain incremental pricing power on network design and care-management; providers face margin compression from lower case volumes and higher administrative costs.

Risk assessment: Tail risk: a national roll-out of prior authorization within 12–24 months could cut elective procedure volumes by 5–15%, creating a >15% EPS hit for specialty device names and 3–8% for hospital operators. Near-term (days–weeks) risk centers on CMS announcements and state pilot metrics; short-term (3–12 months) on AEP enrollment shifts and FY2026 premium notices; long-term (1–3 years) on structural migration to MA and Medigap changing lifetime revenue per beneficiary. Hidden dependency: retiree behavior is sensitive to IRMAA thresholds ($109k single/$218k joint) which will accelerate switching into MA/Medigap if premiums rise.

Trade implications: Direct plays: overweight UNH/HUM (MA/Part D exposure) and PBMs (CVS) — enter within 2 weeks, target +15–25% in 6–12 months; underweight/short HCA, SYK, ZBH — size shorts 1–3% and expect 3–9 month realization. Pair trade: long HUM (3%) / short SYK (2%) to express margin shift from devices to payors. Options: buy 9-month UNH calls (≈ATM to +10% OTM) sized to 1% notional; buy 6–9 month put spreads on HCA or SYK to cap cost.

Contrarian angles: Consensus underprices Medigap premium re-pricing power and stickiness of MA enrollments — a 3–5ppt annual market-share swing to MA over 2 years would be material for UNH/HUM. Reaction may be overdone in device stocks where reduced elective volume in six states represents <10% revenue for large multinationals; these names could rebound if pilots fail to scale. Monitor weekly CMS/state pilot KPIs; if pilot rejection or physician pushback occurs within 90 days, cover shorts aggressively.

Key Decisions for Investors

• Establish a 3% long position in UnitedHealth (UNH) and a 2% long in Humana (HUM) within 2 weeks to capture MA/Part D enrollment tailwinds; target +15–25% gains over 6–12 months, stop-loss at -10% or if CMS signals MA margin compression >150 bps.
• Initiate a 2% short position in Stryker (SYK) and a 2% short in hospital operator HCA within 4 weeks to express downside from reduced elective volumes in pilot states; target 3–9 month horizon, tighten if pilot metrics show <5% utilization decline.
• Implement a pair trade: long HUM (3%) / short SYK (2%) to express payor margin capture vs device volume risk; rebalance after 3 months or if CMS expands prior-authorization pilots to >12 states.
• Buy a 9-month UNH call position (ATM to +10% OTM, size ~1% notional) and simultaneously purchase a 6–9 month put spread on HCA (e.g., 5–12% OTM) to hedge tail risk; adjust if implied volatility moves >30% or CMS publishes national rollout within 90 days.
• Monitor CMS/state prior-authorization pilot updates weekly and AEP enrollment statistics monthly; if CMS expands pilots beyond the initial six states within 90 days, reduce device/hospital exposure by 50% and increase insurer/PBM exposure by 50%.